• Explore /
  • Poster
  • / CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).

CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).

Abstract Poster

Authors

null

Andrew Johns

The University of Texas MD Anderson Cancer Center, Houston, TX

Andrew Johns , Matthew T Campbell , Pavlos Msaouel , Eric Jonasch , Andrew Warren Hahn , Jianjun Gao , Amishi Yogesh Shah , Sangeeta Goswami , Amado J. Zurita , Lance C. Pagliaro , Mehmet Asim Bilen , Aradhana M. Venkatesan , Priya Rao , Pheroze Tamboli , Kanishka Sircar , Rebecca Slack Tidwell , Nizar M. Tannir

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Other GU Kidney and Bladder Cancer

Clinical Trial Registration Number

NCT03541902

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4597)

DOI

10.1200/JCO.2023.41.16_suppl.4597

Abstract #

4597

Poster Bd #

89

Abstract Disclosures

Similar Posters

First Author: Esmail Mutahar Al-Ezzi

First Author: Benjamin L. Maughan

First Author: Bernard Doger de Spéville

First Author: Geoffrey Thomas Gibney